WisdomTree Reports Monthly Metrics for December 2022
WisdomTree, Inc. (NYSE: WT), a global financial innovator, today released monthly metrics for December 2022, including assets under management (AUM) and flow data by asset class.
Key Highlights:
- 2022 net inflows over $12 billion, nearly 16% firm-wide organic growth, with net inflows in 7 of its 8 major product categories during the year.
- Q4 net inflows over $5 billion, WisdomTree’s best quarter since 2015.
- Nine consecutive quarters of net inflows with record year-end AUM of nearly $82 billion.
- U.S. Equity products have generated net inflows in 30 of the prior 31 months, including $472 million in December and $3.3 billion of net inflows for the full year – a 14% pace of organic growth in 2022.
- WisdomTree announced nine new blockchain-enabled funds effective with the SEC, bringing the total to ten effective digital funds. These funds are in addition to the dollar and gold tokens that the firm is making available through WisdomTree PrimeTM.
|
As of December 31, 2022 |
AUM Rollforward
|
Annualized Flow Rate |
|||||||||||
|
|
MTD |
QTD |
YTD |
MTD |
QTD |
YTD |
|||||||
|
Beginning of Period Total AUM |
$80,734 |
|
$70,880 |
|
$77,451 |
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Total Net Flows |
|
|
|
|
|
|
|
|
|
|
|
||
|
U.S. Equity |
$472 |
|
$1,021 |
|
$3,344 |
|
22.3% |
|
19.3% |
|
14.0% |
||
|
International Dev. Mkt Equity |
($114) |
|
$40 |
|
$101 |
|
(12.6%) |
|
1.7% |
|
0.8% |
||
|
Emerging Market Equity |
($7) |
|
($53) |
|
$28 |
|
(0.9%) |
|
(2.8%) |
|
0.3% |
||
|
Fixed Income |
$703 |
|
$3,392 |
|
$11,300 |
|
56.9% |
|
115.1% |
|
259.6% |
||
|
Commodity & Currency |
$1,113 |
|
$796 |
|
($2,911) |
|
64.4% |
|
16.1% |
|
(11.8%) |
||
|
Alternatives |
$16 |
|
$12 |
|
$92 |
|
63.6% |
|
16.2% |
|
35.1% |
||
|
Cryptocurrency |
($7) |
|
($4) |
|
$36 |
|
(54.9%) |
|
(9.3%) |
|
10.1% |
||
|
Leveraged & Inverse |
($15) |
|
$59 |
|
$192 |
|
(10.4%) |
|
15.3% |
|
10.8% |
||
|
Total Net Flows |
$2,162 |
|
$5,264 |
|
$12,181 |
|
31.5% |
|
29.5% |
|
15.7% |
||
|
Market Move |
($910) |
|
$5,842 |
|
($7,646) |
|
|
|
|
|
|
||
|
Current Total AUM |
$81,986 |
|
$81,986 |
|
$81,986 |
|
|
|
|
|
|
||
|
Average Total AUM |
$81,238 |
|
$77,654 |
|
$76,992 |
|
|
|
|
|
|
||
|
Blended Total Average Fee Rate |
|
|
36 bps |
|
38 bps |
|
|
|
|
|
|
||
|
Source: ir.wisdomtree.com |
|||||||||||||
Please visit ir.wisdomtree.com for downloadable spreadsheets containing detailed AUM and flow data by asset class and fund broken out by daily, monthly, quarterly and annual timeframes.
About WisdomTree
WisdomTree is a global financial innovator, offering a well-diversified suite of exchange-traded products (ETPs), models and solutions. We empower investors to shape their future and support financial professionals to better serve their clients and grow their businesses. WisdomTree is leveraging the latest financial infrastructure to create products that provide access, transparency and an enhanced user experience. Building on our heritage of innovation, we are also developing next-generation digital products and structures, including digital funds and tokenized assets, as well as our blockchain-native digital wallet, WisdomTree Prime™.
WisdomTree currently has approximately $83.8 billion in assets under management globally.
For more information about WisdomTree and WisdomTree Prime™, visit: https://www.wisdomtree.com.
Please visit us on Twitter at @WisdomTreeNews.
WisdomTree® is the marketing name for WisdomTree, Inc. and its subsidiaries worldwide.
Cautionary Statement Regarding Forward-Looking Statements
This press release may contain a number of “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our ability to successfully implement our digital assets strategy, including WisdomTree Prime™, and achieve its objectives. These forward-looking statements are based on WisdomTree’s management’s current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside WisdomTree’s management’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements included in this release speak only as of the date of this release. WisdomTree does not undertake any obligation to update its forward-looking statements to reflect events or circumstances after the date of this release except as may be required by the federal securities laws.
Category: Business Update
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005026/en/
Contact information
Media Relations
WisdomTree, Inc.
Jessica Zaloom
+1.917.267.3735
jzaloom@wisdomtree.com / wisdomtree@fullyvested.com
Investor Relations
WisdomTree, Inc.
Jeremy Campbell
+1.646.522.2602
Jeremy.Campbell@wisdomtree.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Begins Commercialization of BYOOVIZ ® , Biosimilar to Lucentis (Ranibizumab), in Europe2.1.2026 09:00:00 EET | Press release
Samsung Bioepis Co., Ltd. today announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis1 (ranibizumab), in Europe. Samsung Bioepis has been working to ensure seamless transfer of commercial rights from Biogen back to Samsung Bioepis, and BYOOVIZ will now be available as a Samsung Bioepis brand across multiple European countries. “This is a significant milestone for Samsung Bioepis as the company continues to strengthen its presence in Europe by expanding its portfolio of directly commercialized products. Leveraging the past three years of experience with EPYSQLI (eculizumab) and the newly launched OBODENCE (denosumab) and XBRYK (denosumab) in Europe, we will continue on our journey to become a fully integrated biopharmaceutical company with end-to-end capabilities from development to commercialization,” said Antonio Rito, Vice President and Head of Europe, at Samsung Bioepis. “We will work closely with payers and healthcare professionals to e
Cessna Citation Ascend Enters Into Service, Redefining Performance and Cabin Experience in the Midsize Business Jet Market31.12.2025 16:00:00 EET | Press release
The Cessna Citation Ascend achieved a major milestone as the first retail customer took delivery of the midsize business jet on Tuesday, December 30, marking the aircraft’s entry into service. Announced in 2023 the aircraft boasts an entirely new cockpit, improved performance and a luxurious flat floor cabin. The Citation Ascend received type certification from the Federal Aviation Administration (FAA) in November 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231586042/en/ Cessna Citation Ascend enters into service, redefining performance and cabin experience in the midsize business jet market. (Photo credit: Textron Aviation) The Cessna Citation Ascend is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “The first Citation Ascend delivery underscores Textron Aviation’s commitment to redefining the midsize segment with an aircraft that blends innovation, efficiency and unmatch
Aster Guardians Global Nursing Award 2026 Worth $250,000 Extends Deadline Till 11 th January 202631.12.2025 15:08:00 EET | Press release
The Aster Guardians Global Nursing Award 2026, an initiative from Aster DM Healthcare – a leading integrated healthcare provider, has announced the extension of its deadline to January 11, 2026. The awards have already received over 134,000 registrations from 214 countries, highlighting its growing global reach and recognition among nurses worldwide. Nurses from around the world can submit their nominations through the dedicated platform at www.asterguardians.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231986766/en/ Aster Guardians Global Nursing Award worth USD 250,000 (Photo: AETOSWire) This year, the prestigious award will be hosted in New Delhi, India, celebrating nursing excellence on a truly global stage. The fourth edition of the awards were held in Dubai, UAE where Nurse Naomi Oyoe Ohene Oti was honoured as the winner for her transformative work in cancer care and education that has shaped oncology nursing
Tecnotree Included as a Representative Provider in Gartner ® Innovation Insight: AI SOC Agents Accelerate CSP SecOps Transformation31.12.2025 12:59:00 EET | Press release
Tecnotree, a global digital platform and services provider for communications service providers (CSPs), today announced that it has been referenced as a Representative Provider alongside Google, Anthropic, Dropzone AI, DRUID, Palo Alto Networks, and Pegasystems in the Gartner® Innovation Insight: “AI SOC Agents Accelerate CSP SecOps Transformation,” published in December 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231210303/en/ Tecnotree Included as a Representative Provider in Gartner® Innovation Insight: AI SOC Agents Accelerate CSP SecOps Transformation The Gartner Innovation Insight examines the emerging role of AI-driven Security Operations Centre (SOC) agents in CSP environments, outlining how these agents are used to automate and augment security operations across signalling, core networks, RAN, Open RAN, and roaming domains. The research discusses use cases such as alert triage, investigation support, thr
UAE’s Medcare Treats First International SMA Patient With Revolutionary Intrathecal Gene Therapy30.12.2025 16:15:00 EET | Press release
Medcare Women & Children Hospital has successfully administered a pioneering intrathecal gene therapy for Spinal Muscular Atrophy (SMA) to Hulus, a three-year-old patient from Turkey. This milestone positions Medcare among the first private healthcare providers worldwide to offer this innovative treatment to an older international patient, overcoming previous age and weight limitations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251230695275/en/ World's first international patient, who received intrathecal gene therapy at Medcare Royal Hospital in Dubai, UAE, along with parents, and the hospital team. (Photo: AETOSWire) SMA is a rare neuromuscular disorder that progressively weakens muscles responsible for movement and breathing. This newly licensed one-time therapy addresses the root genetic cause by delivering a functional SMN1 gene. For Hulus, whose daily routine earlier depended on intensive physiotherapy and hydroth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
